Drugs generally used to cut back ldl cholesterol may in the future assist to deal with prostrate most cancers, new analysis suggests.
A scientific trial with 12 sufferers, performed on the Beatson West of Scotland Cancer Centre in Glasgow, discovered that statins slowed tumour development when given alongside androgen deprivation remedy – a remedy which reduces male hormone ranges.
Professor Hing Leung, who led the analysis, mentioned the research is the “first of its kind to show statins having a detectable effect on prostate cancer growth in patients.” Each yr, round 52,300 persons are identified with prostate most cancers within the UK, figures counsel.
Prof Leung mentioned: “We think statins could stop prostate cancer from making androgens [sex hormones] from cholesterol, cutting off a route for cancer to resist androgen deprivation therapy.
“Castration-resistant prostate cancer, when cancer becomes resistant to hormone therapy, is currently very difficult to treat. If further trials are successful, we could use these already-approved medicines very quickly to offer patients better options for treatment.”
Prostate most cancers requires androgens, equivalent to testosterone, to develop. Current therapies cut back androgen ranges in an try to cease the most cancers from rising. However, in some instances prostate most cancers can change into “castration resistant”, which means it stops responding to those therapies.
Over a six- to eight-week interval, the researchers gave atorvastatin to 12 sufferers whose most cancers had change into proof against the sort of remedy.
The crew then measured ranges of prostate particular antigen (PSA), which is used to estimate tumour development in sufferers with prostate most cancers, and located 11 out of the 12 noticed their PSA ranges fall while taking atorvastatin.
The researchers at the moment are hoping to launch a bigger research to find out if statins could possibly be used extra extensively to deal with prostate most cancers.
Dr Hayley Luxton, a senior analysis impression supervisor at Prostate Cancer UK, mentioned: “We are pleased to have funded this study, which shows encouraging early signs that statins could help slow prostate cancer growth.
“Further research is now needed to understand the best time to add statins to prostate cancer treatment, and to test this approach in a much larger group of men.”
The findings of the research have been welcomed by John Culling, 64, who was identified with an aggressive type of prostrate most cancers in 2019.
John, who lives in Broughty Ferry close to Dundee together with his spouse Margaret, underwent chemotherapy, radiotherapy and hormone remedy which was profitable and is now being monitored.
The father of two mentioned: “The aggressiveness of the prostate cancer I have, means there is a high chance it could come back so it’s a case of waiting and watching.”
A former captain within the military, John is hopeful the present analysis can be additional developed to assist deal with the illness much more successfully sooner or later.
He mentioned: “Knowing that scientists are working in labs and hospitals conducting research and clinical trials, especially with drugs that are already in use for other conditions, gives me hope both for myself and for future generations.
“Hopefully, research like this means even better outcomes for anyone who might have to go through a diagnosis like mine.”